摘要 |
<p>The invention concerns methods, compositions and kits for use in preparing a medicament and vaccine for measles virus comprising an Attenuated Modified Vaccinia Virus Ankara (MVA) strain encoding hemagglutinin protein, fusion protein, and nucleoprotein of measles virus (MVA-Measles). The recombinant virus induced superior cellular and humoral responses to the measles virus when compared to Measles vaccine Rouvax®. Both T cell and B cell immune responses to the recombinant MVA were observed not only in adult animals, but also in newborn and juvenile animals. Results in adult humans showed that MVA-Measles induces a strong immune response, is safe and well tolerated.</p> |